Psychiatric and neuropsychological manifestations of systemic lupus erythematosus

Acta Biomedica

Volumn 82, Issue 2, 2011, Pages 97-114

  Fietta, Pierluigi ^a   Fietta, Pieranna ^b   Delsante, Giovanni ^b  

^a Hospital of Lodi   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Acute confusional state; Anxiety disorder; Cognitive disorder; Delirium; Depression; Mood disorder; Neuropsychiatric systemic lupus erythematosus; Psychiatric and neuropsychological syndromes; Psychopathology; Psychosis

Indexed keywords

ACETYLSALICYLIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; AZATHIOPRINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; HALOPERIDOL; IMMUNOGLOBULIN; LITHIUM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; RITUXIMAB; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ACUTE CONFUSION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY DISORDER; BIPOLAR DISORDER; CATATONIA; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DRUG MEGADOSE; DYSKINESIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; GENETIC POLYMORPHISM; HUMAN; HYPERPROLACTINEMIA; IMMUNOPATHOLOGY; INFLAMMATION; IRRITABILITY; ISCHEMIA; LOW DRUG DOSE; MENTAL DISEASE; MOOD DISORDER; MOTOR ACTIVITY; NEUROIMAGING; NEUTROPENIA; PATHOGENESIS; PREVALENCE; PSYCHOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; ANIMAL; ARTICLE; BRAIN VASCULITIS; CHILD; COMORBIDITY; DISEASE MODEL; MENTAL STRESS; PSYCHOLOGICAL ASPECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUICIDE;

ADULT; ANIMALS; ANXIETY DISORDERS; CHILD; COMORBIDITY; DISEASE MODELS, ANIMAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MOOD DISORDERS; PSYCHOTIC DISORDERS; STRESS, PSYCHOLOGICAL; SUICIDE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84860550724     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369: 587-96.
2. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68.
3. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 2156-62.
4. Mok CC, Lau CS, Wong RW. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766-71.
5. Mok CC, To CH, Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 2006; 85: 221-8.
6. Al-Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009; 18: 465-73.
7. Karassa FB, Afeltra A, Ambrozic A et al. Accuracy of antiribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54: 312-24.
8. Hanly JG, Urowitz MB, Su L et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008; 59: 721-9.
9. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 2004; 43: 1555-60.
10. Sanna G, Bertolaccini ML, Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-92.
11. Afeltra A, Garzia P, Mitterhofer AP et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-10.
12. Brey RL, Holliday SL, Saklad AR et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214-20.
13. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500.
14. Avcin T, Benseler SM, Tyrrell PN, Cucnik S, Silverman ED. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 206-13.
15. Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004; 23: 395-9.
16. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152: 550-6.
17. Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006; 33: 1873-7.
18. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007; 16: 564-71.
19. Yu HH, Lee JH, Wang LC, Yang YH, Chiang BL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 2006; 15: 651-7.
20. Tucker LB, Uribe AG, Fernández M et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008; 17: 314-22.
21. Singh S, Gupta MK, Ahluwalia J, Singh P, Malhi P. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol Int 2009; 29: 1455-61.
22. Sibbitt WL Jr, Brandt JR, Johnson CR et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29: 1536-42.
23. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002; 41: 605-18.
24. Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005; 31: 273-98.
25. Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007; 56: 265-73.
26. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002; 41: 619-30.
27. Senécal JL, Raymond Y. The pathogenesis of neuropsychiatric manifestations in systemic lupus erythematosus: a disease in search of autoantibodies, or autoantibodies in search of a disease? J Rheumatol 2004; 31: 2093-8.
28. Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 2009; 9: 449-56.
29. Matus S, Burgos PV, Bravo-Zehnder M et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 2007; 204: 3221-34.
30. Lapteva L, Nowak M, Yarboro CH et al. Anti-N-methyl-Daspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2505-14.
31. Williams RC Jr, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1239-47.
32. Sasajima T, Watanabe H, Sato S, Sato Y, Ohira H. Antitriosephosphate isomerase antibodies in cerebrospinal fluid are associated with neuropsychiatric lupus. J Neuroimmunol 2006; 181: 150-6.
33. West SG. Lupus and the central nervous system. Curr Opin Rheumatol 1996; 8: 408-14.
34. Fietta P, Fietta P, Delsante G. Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin Neurosci 2009; 63: 613-22.
35. Seguí J, Ramos-Casals M, García-Carrasco M et al. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus 2000; 9: 584-8.
36. ACR ad hoc Committee on Neuropsychiatry Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
37. Frances A, Pincus HA, First MB et al. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association; 1994.
38. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
39. Hochberg MC. Updating the American College of Rheumatology for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
40. Mesulam MM. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol 1990; 28: 597-613.
41. Hawro T, Maria Krupińska-Kun, Jolanta Rabe-Jabłońska et al. Psychiatric disorders in patients with systemic lupus erythematosus: association of anxiety disorder with short disease duration. Rheumatol Int 2010 Dec 7. [Epub ahead of print]
42. Hanly JG, Cassell K, Fisk JD. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum 1997; 40: 1542-3.
43. Ainiala H, Hietaharju A, Dastidar P et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 2004; 50: 858-65.
44. Olazarán J, López-Longo J, Cruz I, Bittini A, Carreño L. Cognitive dysfunction in systemic lupus erythematosus: prevalence and correlates. Eur Neurol 2009; 62: 49-55
45. Abdel-Nasser AM, Ghaleb RM, Mahmoud JA, Khairy W, Mahmoud RM. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol 2008; 27: 1377-85.
46. Tomietto P, Annese V, D'Agostini S et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 2007; 57: 1461-72.
47. Brunner HI, Ruth NM, German A et al. Initial validation of pediatric automated neuropsychological assessment metrics for childhood-onset systemic lupus erythematosus. Arthritis Rheum 2007; 57: 1174-82.
48. Ainiala H, Hietaharju A, Loukkola J et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndrome: a population-based evaluation. Arthritis Rheum 2001; 45: 419-23.
49. Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 3286-98.
50. Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51: 810-8.
51. Ad hoc Committee on Lupus Response Criteria: Cognition Sub-committee, Mikdashi JA, Esdaile JM, Alarcón GS et al. Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007; 16: 418-25.
52. Hanly JG, Omisade A, Su L, Farewell V, Fisk JD. Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. Arthritis Rheum 2010 May; 62: 1478-86.
53. Carlomagno S, Migliaresi S, Ambrosone L, Sannino M, Sanges G, Iorio G. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol 2000; 247: 273-9.
54. Monastero R, Bettini P, Zotto E et al. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci 2001; 184: 33-9.
55. Leritz E, Brandt J, Minor M, Reis-Jensen F, Petri M. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. J Clin Exp Neuropsychol 2002; 24: 527-33.
56. Shucard JL, Parrish J, Shucard DW, McCabe DC, Benedict RH, Ambrus J Jr. Working memory and processing speed deficits in systemic lupus erythematosus as measured by the paced auditory serial addition test. J Int Neuropsychol Soc 2004; 10: 35-45.
57. Emori A, Matsushima E, Aihara O et al. Cognitive dysfunction in systemic lupus erythematosus. Psychiatry Clin Neurosci 2005; 59: 584-9.
58. Benedict RH, Shucard JL, Zivadinov R, Shucard DW. Neuropsychological impairment in systemic lupus erythematosus: a comparison with multiple sclerosis. Neuropsychol Rev 2008; 18: 149-66.
59. Levy DM, Ardoin SP, Schanberg LE. Neurocognitive impairment in children and adolescents with systemic lupus erythematosus. Nat Clin Pract Rheumatol 2009; 5: 106-14.
60. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005; 64: 297-303.
61. Bosma GP, Steens SC, Petropoulos H et al. Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3195-202.
62. Cantú-Brito C, Baizabal-Carvallo JF, Alonso-Juárez M, García-Ramos G. The clinical significance of microembolic signals in patients with systemic lupus erythematosus. Neurol Res 2010; 32: 134-8.
63. Denburg SD, Denburg JA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 2003; 12: 883-90.
64. Kowal C, DeGiorgio LA, Lee JY et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006; 103: 19854-9.
65. Lu XY, Chen XX, Huang LD, Zhu CQ, Gu YY, Ye S. Anti-alpha-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis. PLoS One 2010; 5: e11124.
66. Kozora E, Laudenslager M, Lemieux A, West SG. Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol Soc 2001; 7: 745-54.
67. Lapteva L, Yarboro CH, Roebuck-Spencer T et al. Cognitive dysfunction and serum neuropeptides in systemic lupus erythematosus. Arthritis Rheum 2006; 54 (Suppl. 9): S293.
68. Oroszi G, Lapteva L, Davis E et al. The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 1330-5.
69. Peterson PL, Axford JS, Isenberg D. Imaging in CNS lupus. Best Pract Res Clin Rheumatol 2005; 19: 727-39.
70. Spinosa MJ, Bandeira M, Liberalesso PB et al. Clinical, laboratory and neuroimage findings in juvenile systemic lupus erythematosus presenting involvement of the nervous system. Arq Neuropsiquiatr 2007; 65: 433-9.
71. Ainiala H, Dastidar P, Loukkola J et al. MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand J Rheumatol 2005; 34: 376-82.
72. Jung RE, Segall JM, Grazioplene RG, Qualls C, Sibbitt WL, Roldan CA. Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. PLoS One 2010; 5: e9302.
73. Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2783-9.
74. Muscal E, Bloom DR, Hunter JV, Myones BL. Neurocognitive impairments and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution. Lupus 2010; 19: 268-79.
75. Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998; 41: 41-7.
76. Sabbadini MG, Manfredi AA, Bozzolo E et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 1999; 8: 11-9.
77. Sibbitt WL Jr, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2026-38.
78. Kovacs JA, Urowitz MB, Gladman DD, Zeman R. The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J Rheumatol 1995; 22: 1247-53.
79. Falcini F, De Cristofaro MT, Ermini M et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study. Single photon emission computed tomography. J Rheumatol 1998; 25: 583-8.
80. Russo R, Gilday D, Laxer RM, Eddy A, Silverman ED. Single photon emission computed tomography scanning in childhood systemic lupus erythematosus. J Rheumatol 1998; 25: 576-82.
81. Mathieu A, Vacca A, Serra A et al. Defective cerebral gamma-aminobutyric acid-A receptor density in patients with systemic lupus erythematosus and central nervous system involvement. An observational study. Lupus 2010; 9: 918-26.
82. Kao CH, Ho YJ, Lan JL, Changlai SP, Liao KK, Chieng PU. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum 1999; 42: 61-8.
83. Weiner SM, Otte A, Schumacher M, Klein R et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 2000; 59: 377-85.
84. Carbotte RM, Denburg SD, Denburg JA, Nahmias C, Garnett ES. Fluctuating cognitive abnormalities and cerebral glucose metabolism in neuropsychiatric systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1992; 55: 1054-9.
85. Bosma GP, Rood MJ, Zwinderman AH, Huizinga TW, van Buchem MA. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum 2000; 43: 48-54.
86. Emmer BJ, Steens SC, Steup-Beekman GM et al. Detection of change in CNS involvement in neuropsychiatric SLE: a magnetization transfer study. J Magn Reson Imaging 2006; 24: 812-6.
87. Emmer BJ, Steup-Beekman GM, Steens SC, Huizinga TW, van Buchem MA, van der Grond J. Correlation of magnetization transfer ratio histogram parameters with neuropsychiatric systemic lupus erythematosus criteria and proton magnetic resonance spectroscopy: association of magnetization transfer ratio peak height with neuronal and cognitive dysfunction. Arthritis Rheum 2008; 58: 1451-7.
88. DiFrancesco MW, Holland SK, Ris MD et al. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. Arthritis Rheum 2007; 56: 4151-63.
89. Filley CM, Kozora E, Brown MS et al. White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus. Cogn Behav Neurol 2009; 22: 38-44.
90. Lim MK, Suh CH, Kim HJ, Systemic lupus erythematosus: brain MR imaging and single-voxel hydrogen 1 MR spectroscopy. Radiology 2000; 217: 43-9.
91. Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL Jr. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999; 26: 81-5.
92. Friedman SD, Stidley CA, Brooks WM, Hart BL, Sibbitt WL Jr. Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. Radiology 1998; 209: 79-84.
93. Sibbitt WL Jr, Haseler LJ, Griffey RR, Friedman SD, Brooks WM. Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. AJNR Am J Neuroradiol 1997; 18: 1271-7.
94. Harrison MJ, Morris KA, Horton R et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 2005; 65: 1325-7.
95. Karnik NS, Joshi SV, Paterno C, Shaw R. Subtypes of pediatric delirium: a treatment algorithm. Psychosomatics 2007; 48: 253-7.
96. Kasitanon N, Louthrenoo W, Piyasirisilp S, Sukitawu W, Wichainun R. Neuropsychiatric manifestations in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2002; 20: 179-85.
97. Haghighi AB, Haza SG. Neuropsychiatric manifestations of systemic lupus erythematosus: Iranian experience. Ann Indian Acad Neurol 2010; 13: 108-11.
98. Katsumata Y, Harigai M, Kawaguchi Y et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol 2007; 34: 2010-7.
99. Kodama K, Okada S, Hino T et al. Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 1995; 58: 307-11.
100. Nishimura K, Omori M, Horikawa N, Tanaka E, Furuya T, Harigai M. Risperidone in the treatment of acute confusional state (delirium) due to neuropsychiatric lupus erythematosus: case report. Int J Psychiatry Med 2003; 33: 299-303.
101. Su JA, Wu CH, Tsang HY. Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report. Gen Hosp Psychiatry 2007; 29: 75-7.
102. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotic for delirium. Cochrane Database Syst Rev 2007 Apr 18; (2): CD005594.
103. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005; 66 (Suppl. 7): 29-40.
104. Liu CY, Juang YY, Liang HY, Lin NC, Yeh EK. Efficacy of risperidone in treating the hyperactive symptoms of delirium. Int Clin Psychopharmacol 2004; 19: 165-8.
105. Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2006 Apr 19; (2): CD002265.
106. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008; 14: 1261-9.
107. Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999; 60 (Suppl. 22): 12-7.
108. Jarpa E, Babul M, Calderon J et al. Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus 2010 Nov 15. [Epub ahead of print]
109. Conti F, Alessandri C, Bompane D et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther 2004; 6: R366-72.
110. Nery FG, Borba EF, Viana VS et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 695-700.
111. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004; 9: 716-23.
112. Sakolsky D, Birmaher B. Pediatric anxiety disorders: management in primary care. Curr Opin Pediatr 2008; 20: 538-43.
113. Walkup JT, Albano AM, Piacentini J et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359: 2753-66.
114. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 822-9.
115. Karassa FB, Magliano M, Isenberg DA. Suicide attempts in patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 58-60.
116. Schneebaum AB, Singleton JD, West SG et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90: 54-62.
117. Hanly JG, Urowitz MB, Siannis F et al; Systemic Lupus International Collaborating Clinics. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58: 843-53.
118. Katzav A, Solodeev I, Brodsky O et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 2007; 56: 938-48.
119. Ebert T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 2005; 14: 571-5.
120. Giovacchini G, Mosca M, Manca G et al. Cerebral blood flow in depressed patients with systemic lupus erythematosus. J Rheumatol 2010; 37: 1844-51.
121. Oda K, Matsushima E, Okubo Y et al. Abnormal regional cerebral blood flow in systemic lupus erythematosus patients with psychiatric symptoms. J Clin Psychiatry 2005; 66: 907-13.
122. Brelinski L, Cottencin O, Guardia D et al. Catatonia and systemic lupus erythematosus: a clinical study of three cases. Gen Hosp Psychiatry 2009; 31: 90-2.
123. Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L. Antipsychotics in bipolar disorders. Encephale 2004; 30: 417-24. [French]
124. Nutt DJ, Davidson JR, Gelenberg AJ et al. International consensus statement on major depressive disorder. J Clin Psychiatry 2010; 71 Suppl E1: e08.
125. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008; 47: 1498-502.
126. Appenzeller S, Cendes F, Costallat LT. Acute psychosis in systemic lupus erythematosus. Rheumatol Int 2008; 28: 237-43.
127. Adelowo OO, Oguntona AS, Ojo O. Neuropsychiatric systemic lupus erythematosus among Nigerians. Afr J Med Med Sci 2009; 38: 33-8.
128. Matsukawa Y, Sawada S, Hayama T, Usui H, Horie T. Suicide in patients with systemic lupus erythematosus: a clinical analysis of seven suicidal patients. Lupus 1994; 3: 31-5.
129. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992; 35: 417-22.
130. Ramos PC, Mendez MJ, Ames PR, Khamashta MA, Hughes GR. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 295-9.
131. Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115: 59-62.
132. Baca V, Lavalle C, García R et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26: 432-9.
133. Muscal E, Nadeem T, Li X, Mian A, Harris TB. Evaluation and treatment of acute psychosis in children with systemic lupus erythematosus: consultation-liaison service experiences at a tertiary-care pediatric institutions. Psychosomatics 2010; 51: 508-14.
134. Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-5.
135. Mostafa GA, Ibrahim DH, Shehab AA, Mohammed AK. The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus. J Neuroimmunol 2010; 227: 195-201.
136. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narváez A et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1242-50.
137. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881-7.
138. Ballok DA, Woulfe J, Sur M, Cyr M, Sakic B. Hippocampal damage in mouse and human forms of systemic autoimmune disease. Hippocampus 2004; 14: 649-61.
139. Gao HX, Sanders E, Tieng AT, Putterman C. Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice. J Neuroimmunol 2010; 229: 112-22.
140. Sakic B, Kolb B, Whishaw IQ, Gorny G, Szechtman H, Denburg JA. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J Neuroimmunol 2000; 111: 93-101.
141. Nomura K, Yamano S, Ikeda Y et al. Asymptomatic cerebrovascular lesions detected by magnetic resonance imaging in patients with systemic lupus erythematosus lacking a history of neuropsychiatric events. Intern Med 1999; 38: 785-95.
142. Bertsias GK, Ioannidis JPA, Aringer M et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-82.
143. He J, Kong J, Tan QR, Li XM. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adh Migr 2009; 3: 129-37.
144. Sthoeger ZM, Sharabi A, Molad Y et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 2009; 33: 77-82.
145. Lapter S, Marom A, Meshorer A et al. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis Rheum 2009; 60: 3744-54.